Predictive factors for long-term engraftment of autologous blood stem cells

Bone Marrow Transplant. 2000 Dec;26(12):1299-304. doi: 10.1038/sj.bmt.1702708.

Abstract

Data from 170 consecutive patients aged 19-66 years (median age 46 years) who underwent unmanipulated autologous blood stem cell transplant (ASCT) were analyzed to determine if total CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+90+, CD34+33-, CD34+38-, CD34+38-DR-), peripheral blood CD34+ cell (PBCD34+) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or re-induction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n = 4). Of the remaining 136 patients, 46% had low WBC ( < 4 x 10(9)/l), 41% low platelets (<150 x 10(9)/l), and 34% low hemoglobin ( < 120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34+ cell dose/kg and the PBCD34+ count correlated with 6 month blood counts better than any subset of CD34+ cells or any clinical factor. The PBCD34+ count was overall a stronger predictor of 6 month blood counts than was the total CD34+ cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34+ cells and clinical factors are inferior to the total CD34+ cell dose/kg and PBCD34+ count in predicting 6 month blood counts following ASCT.

MeSH terms

  • Adult
  • Aged
  • Antigens, CD34 / analysis
  • Blood Cell Count
  • Blood Transfusion, Autologous / standards*
  • Female
  • Follow-Up Studies
  • Graft Survival*
  • Hematopoietic Stem Cell Transplantation / standards
  • Humans
  • Immunophenotyping
  • Male
  • Middle Aged
  • Neoplasms / therapy
  • Predictive Value of Tests
  • Prognosis
  • Retrospective Studies
  • Statistics, Nonparametric
  • Transplantation, Autologous / standards*

Substances

  • Antigens, CD34